A Phase II Study of Siltuximab to Decrease Symptoms after Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma and Amyloidosis

Full Title

Phase II Study of Interleukin 6 Blockade With Siltuximab to Decrease Symptom Burden in Patients age 60-75 Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma and AL Amyloidosis

Purpose

During an autologous stem cell transplant (ASCT), high-dose chemotherapy is given before reinfusion of a patient’s own stem cells. This treatment is used for some patients with multiple myeloma and amyloidosis. The high doses of chemotherapy often cause symptoms, however, especially in older patients, such as fatigue, nausea, vomiting, pain, diarrhea, and sleep disturbances. These symptoms can interfere with daily activities and prolong recovery.

In this study, researchers are assessing the safety and effectiveness of an investigational drug called siltuximab to reduce symptoms in patients age 60-75 after ASCT for multiple myeloma or amyloidosis. Siltuximab inhibits the production of an inflammatory protein called interleukin-6 (IL-6) which is thought to cause the symptoms that develop after ASCT. Siltuximab is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma or systemic light chain amyloidosis that will be treated with ASCT.
  • Patients may not have received prior therapy that targets IL-6.
  • This study is for patients age 60-75.

For more information about this study and to inquire about eligibility, please call 877-836-2268.

Protocol

17-365

Phase

II

Investigator